Drug Trial Radar · NCT05066672
Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression
Last checked: Nov 19, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
250
Actual
Start
Jan 18, 2022
Primary completion
Jan 21, 2025
Study completion Jan 21, 2025
Sponsor
- Lead sponsor
- Navitor Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Supernus Pharmaceuticals, Inc.
- First posted
- Oct 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of NV-5138 in adults with TRD
Conditions
- Treatment Resistant Depression
Interventions
NV-5138Drug
NV-5138 is a novel, orally bioavailable, selective, direct enhancer of mTORC1 cellular signaling
matched placeboDrug
matched placebo oral capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score.Time frame: Baseline to Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Northwest Clinical Research Center, Inc.
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.